← Back to Search

Pioglitazone 30 mg for Insulin Resistance

Phase 2
Waitlist Available
Research Sponsored by St. Louis University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial looks at whether giving the drug pioglitazone to men with prostate cancer who are also on ADT will help improve insulin resistance.

Eligible Conditions
  • Insulin Resistance
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
insulin sensitivity
Secondary outcome measures
Insulin signaling (Insulin receptor substrate expression in fat tissue)

Side effects data

From 2013 Phase 3 trial • 936 Patients • NCT01183013
9%
Oedema
7%
Dizziness
7%
Oedema peripheral
6%
Hyperglycaemia
6%
Nasopharyngitis
5%
Back pain
5%
Pain in extremity
5%
Urinary tract infection
5%
Upper respiratory tract infection
4%
Hypertension
4%
Headache
3%
Arthralgia
2%
Acute myocardial infarction
2%
Diarrhoea
2%
Bronchitis
1%
Upper gastrointestinal haemorrhage
1%
Device related infection
1%
Chronic lymphocytic leukaemia
1%
Diverticulum
1%
Pulmonary embolism
1%
Hypertensive crisis
1%
Peripheral ischaemia
1%
Cardiopulmonary failure
1%
Gastric haemorrhage
1%
Gastric ulcer
1%
Cholecystitis acute
1%
Traumatic fracture
1%
Iron deficiency anaemia
1%
Supraventricular tachycardia
1%
Vomiting
1%
Infection
1%
Squamous cell carcinoma of skin
1%
Chronic obstructive pulmonary disease
1%
Hydrocele
1%
Gastroenteritis
1%
Craniocerebral injury
1%
Encephalitis
1%
Pleural effusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lina5Pio30/Lina5Pio30
Pio30/Pio30
Pio15/Pio30
Lina5/Lina5
Lina5Pio15/Lina5Pio30
Lina5Pio45/Lina5Pio45
Pio45/Pio45

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PioglitazoneExperimental Treatment1 Intervention
Group II: placeboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pioglitazone 30 mg
2021
Completed Phase 4
~1670

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
194 Previous Clinical Trials
43,405 Total Patients Enrolled
1 Trials studying Insulin Resistance

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment open for this particular research effort?

"According to the information on clinicaltrials.gov, this research is searching for participants and has been available since December 1st 2021 with edits having taken place as recently as June 30th 2022."

Answered by AI

What is the usual purpose of administering Pioglitazone 30 mg?

"Pioglitazone 30 mg is typically prescribed to treat diabetes, yet it can also assist patients in tackling diabetic neuralgia and promoting a healthy lifestyle with diet and exercise."

Answered by AI

Is the age cut-off for participation in this research trial below 30 years of age?

"Those hoping to be included in this clinical trial must fall within the age range of 18-85. The study features 101 studies for minors and 1422 research opportunities for seniors."

Answered by AI

Is it possible for me to become a participant in this clinical trial?

"To qualify for this clinical trial, potential participants must exhibit insulin resistance and be between 18 to 85 years old. The total number of admitted patients is 44 individuals."

Answered by AI

How many participants are enrolled in this research endeavor?

"Affirmative. According to the information on clinicaltrials.gov, this medical research was established on December 1st 2021 and is presently seeking 44 participants from a single site. The trial has been recently updated as of June 30th 2022."

Answered by AI

Does the administration of Pioglitazone 30 mg pose any substantial health risks?

"Our group at Power analyzed the safety of Pioglitazone 30 mg and determined that this Phase 2 trial, which has some evidence supporting its security but no proof for efficacy, deserves a rating of 2."

Answered by AI

Could you provide a catalog of research projects utilizing Pioglitazone 30 mg?

"Presently, there are 31 clinical trials examining the efficacy of Pioglitazone 30 mg. Of those, 4 have reached Phase 3 status. These studies primarily occur in Lausanne, Vaud; however 69 other locations worldwide are running these same trials."

Answered by AI
~0 spots leftby Mar 2025